Survival benefit of extended lymphadenectomy in endometrial cancer: a meta-analysis with risk-stratified subgroup analysis - Top-Institutions - MDSpire

Survival benefit of extended lymphadenectomy in endometrial cancer: a meta-analysis with risk-stratified subgroup analysis

  • By

  • Yunlong Fan

  • Jun Zhu

  • Lingling Jiang

  • Jia Xu

  • Jinqun Huang

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Leiden University Medical Center
    Leiden University Medical Center

    Leiden, South Holland

    Key Differentiators

    • Gynecologic Oncology

  • #2

    Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford
    Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford

    Oxford, England

    Key Differentiators

    • Public Health
    • Clinical Trials

  • #3

    University of Southern California
    University of Southern California

    Los Angeles, California

    Key Differentiators

    • Oncology
    • Public Health

  • #4

    Early Breast Cancer Trialists’ Collaborative Group
    Early Breast Cancer Trialists’ Collaborative Group

    N/A, N/A

    Key Differentiators

    • Oncology

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Hematology

Original Source(s)

Survival benefit of extended lymphadenectomy in endometrial cancer: a meta-analysis with risk-stratified subgroup analysis

  • by Yunlong Fan, Jun Zhu, Lingling Jiang, Jia Xu, Jinqun Huang

  • June 10, 2026

Related Content

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

Occult ovarian carcinoid in pregnancy: a case report and literature review

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors